Intrathecal interleukin-6 levels are associated with progressive disease and clinical severity in multiple sclerosis.

ABSTRACT:

Background

MS is characterized by persistent central nervous system (CNS) inflammation. Investigating the CNS-compartmentalized inflammation associated with progressive MS could uncover new biomarkers and therapeutic targets. Cerebrospinal fluid (CSF) interleukin-6 (IL-6) can be markedly elevated in neuroinflammatory conditions, such as neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease. This study investigated the association between CSF IL-6 levels, progressive disease, and disease severity in MS.

Methods

Advanced technologies, including single-molecule arrays and microfluidics, were used to analyse CSF samples from individuals with MS at the time of diagnosis for IL-6. IL-6 levels were then correlated with clinical c

SUBMITTER: Itorralba J 

PROVIDER: S-EPMC11963510 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature